		<u>analysis</u>	significance	factor		<u>analysis</u>	significance	factor
	Plasma concentrations				Home cage activity			
	(nicotine [µg·l-1])	multivariate	F _(3,12) =0.71, p=0.415	sex·genotype	(time active [%])	repeated	F _(3,39) =0.63, p=0.641*	treatment·time
		multivariate	F _(1,12) =1.69, p=0.621	genotype		repeated	(3,37)	·sex·genotype
		multivariate	$F_{(1,12)}=0.74$, p=0.406	sex		measures	F _(3,39) =0.55, p=0.801*	time-treatment
l	(cotinine [µg·l-1])	multivariate	F _(3,12) =0.49, p=0.499	sex·genotype		repeated	F _(3,39) =0.58, p=0.676*	time·genotype
		multivariate	F _(1,12) =0.26, p=0.218	genotype		repeated	En an -0.60 p-0.660*	time-sex
		multivariate	F _(1,12) =0.30, p=0.593	sex		measures	1 (3,39)=0.000, p=0.000	time sex
	Caloric intake					measures	F _(3,39) =3.65, p=0.013*	time
	7 12 days food matriation				Working memory			
	(food consumption [g:d 1])	univariata	E = -0.17 p = -0.686	trastmant.cav.ganotyna	forced alternation training			
	(100d consumption [g d-1])	univariate	$F_{(7,9)}=0.17$, p=0.000 F016, p=0.310	treatment	torced alternation training	repeated		
		univariate	$\Gamma_{(1,9)}=0.10, p=0.310$ E = -0.25 p=0.631	genotype	(time reward collected [s])	measures	$F_{(3,169)}=0.94, p=0.474*$	treatment time sex genotype
		univariate	$F_{(1,9)}=0.22, p=0.651$ $F_{(1,9)}=0.22, p=0.651$	sex		repeated measures	$F_{(3,169)}=0.74, p=0.551*$	time·genotype·sex
	free access to food					repeated measures	F _(3,169) =0.65, p=0.716*	time·treatment·sex
	(animal weight [g] at day 6)	multivariate	$F_{(7,71)}$ =0.07, p=0.797	treatment·sex·genotype		repeated	F _(3,169) =0.70, p=0.670*	time·treatment
		multivariate	F _(1,71) =0.77, p=0.384	treatment		repeated		
		multivariate	F _(1,71) =0.20, p=0.657	genotype		measures	$F_{(3,169)}=0.47, p=0.730*$	time·genotype
		multivariate	$F_{(1,71)}$ =75.61, p<0.001	sex		repeated	F _(3,39) =2.75, p=0.037*	time∙sex
	(animal weight [g] at day 14)	multivariate	F _(7,71) =0.12, p=0.730	treatment·sex·genotype		repeated	Ea.co=34.36 p<0.001*	time
		multivariate	F _(1,71) =0.83, p=0.366	treatment		measures	1 (3,169)=54.50, p<0.001	time
		multivariate	$F_{(1,71)}=0.19, p=0.663$	genotype	paired-trial alternation test			
		multivariate	$F_{(1,71)}$ =93.34, p<0.001	sex	(% correct alternations)	univariate	F _(2,44) =3.84, p=0.029	treatment·sex·genotype
	Two bottle choice preference					univariate	$F_{(2,44)}$ =6.63, p=0.003	treatment·genotype
		repeated				univariate	F _(2,44) =1.70, p=0.936	treatment
	(nicotine cons. [µg·g-1 BW])	measures	F _(1,42) =0.77, p=0.439*	sex·time·genotype		univariate	$F_{(1,44)}=0.14, p=0.708$	genotype
		repeated measures	$F_{(1,42)}$ =2.28, p=0.125*	time·genotype	- split by treatment	univariate	F _(1,44) =6.63, p=0.199	sex
l		repeated	F _(1,42) =1.83, p=0.179*	sex·time	saline	univariate	F _(1,17) =8.72, p=0.009	genotype
		repeated	E = -27.52 m < 0.001*	time	nicotine [24 mg·kg-1·d-1]	univariate	F _(1,18) =4.89, p=0.040	genotype
		measures	$\Gamma_{(1,42)}=37.53, p<0.001^{+1}$	time	- split by genotype			
	(nicotine preference [%])	repeated measures	F _(5,135) =1.23, p=0.297*	sex·time·genotype	WT	univariate	F _(2,25) =3.16, p=0.060	treatment
		repeated measures	$F_{(5,135)}=0.48$, p=0.795*	time·genotype	saline vs nicotine (24 mg)	Bonferoni	p=0.033	treatment
		repeated measures	F _(5,135) =2.01, p=0.081*	sex·time	TG post hoc	univariate	F _(2,22) =4.56, p=0.022	treatment
l		repeated measures	F _(5,135) =0.83, p=0.539*	time	saline vs nicotine (24 mg)	Bonferoni	p=0.021	treatment

	analysis	significance	factor		analysis	significance	factor
PPI				(% inhibition at $+15 \text{ dB}$)	multivariate	$F_{(7,71)}=5.133$, p=0.027	treatment·sex·genotype
<u>day 6</u>				- split by sex			0 11
(% inhibition at +5 dB)	multivariate	F _(7,71) =6.41, p=0.014	treatment·sex·genotype	males	multivariate	F _(3,36) =0.46, p=0.503	treatment·genotype
- split by sex				females	multivariate	$F_{(3,35)}=6.55, p=0.015$	treatment·genotype
males	multivariate	F _(3,36) =1.96, p=0.170	treatment·genotype	split by genotype			
females	multivariate	F _(3,35) =7.11, p=0.012	treatment·genotype	WT	multivariate	F _(1.18) =1.90, p=0.185	treatment
split by genotype				TG	multivariate	$F_{(1,17)}=4.86$, p=0.041	treatment
WT	multivariate	$F_{(1,18)}$ =1.99, p=0.176	treatment	~			
TG	multivariate	$F_{(1,17)}$ =5.54, p=0.031	treatment	Social recognition			
(% inhibition at +10 dB)	multivariate	F _(7,71) =3.07, p=0.084	treatment·sex·genotype	social interaction (1st exp.)			
- split by sex				(interaction time [s])	univariate	F _(7,71) =0.53, p=0.467	treatment·sex·genotype
males	multivariate	F _(3,36) =0.81, p=0.814	treatment·genotype		univariate	F _(7,71) =0.01, p=0.971	treatment·sex
females	multivariate	F _(3,35) =3.51, p=0.070	treatment·genotype		univariate	F _(7,71) =0.04, p=0.845	sex·genotype
split by genotype					univariate	F _(1,71) =1.43, p=0.236	treatment
WT	multivariate	$F_{(1,18)}$ =5.54, p=0.379	treatment		univariate	F _(1,71) =0.24, p=0.630	genotype
TG	multivariate	$F_{(1,17)}$ =4.32, p=0.053	treatment		univariate	F _(1,71) =5.60, p=0.021	sex
(% inhibition at +15 dB)	multivariate	F _(7,71) =8.43, p=0.006	treatment·sex·genotype	2h intertrial			
- split by sex				(interaction time [s])	univariata	E -0.32 p-0.575	treatment·object·
males	multivariate	F _(3,36) =0.81, p=0.373	treatment·genotype	(interaction time [s])	univariate	P(15,60)=0.52, p=0.575	genotype·sex
females	multivariate	F _(3,35) =6.47, p=0.013	treatment·genotype		univariate	$F_{(15,60)}=4.54, p=0.037$	treatment·object·genotype
split by genotype					univariate	$F_{(1,60)}=0.19, p=0.669$	treatment
WT	multivariate	$F_{(1,18)}=2.55, p=0.128$	treatment		univariate	$F_{(1,60)}=0.05, p=0.818$	genotype
TG	multivariate	$F_{(1,17)}=9.63, p=0.006$	treatment		univariate	$F_{(1,60)}=6.60, p=0.013$	object
<u>day 14</u>					univariate	$F_{(1,60)}=0.31, p=0.578$	sex
(% inhibition at +5 dB)	multivariate	F _(7,71) =6.51, p=0.013	treatment·sex·genotype	- split by genotype		F (7) 0.015	
- split by sex				WT	univariate	$F_{(3,36)}=6.53, p=0.015$	object
males	multivariate	F _(3,36) =1.07, p=0.309	treatment·genotype	split by treatment		F F 00 0.017	
females	multivariate	$F_{(3,35)}$ =7.04, p=0.012	treatment·genotype	saline	univariate	$F_{(1,18)} = 7.00, p = 0.016$	object
split by genotype				nicotine	univariate	$F_{(1,18)}=0.99, p=0.340$	object
WT	multivariate	$F_{(1,18)}$ =2.78, p=0.113	treatment	1G	univariate	$F_{(3,32)}=3.12, p=0.087$	treatmentobject
TG	multivariate	$F_{(1,17)}=4.54, p=0.048$	treatment	split by treatment		F	
(% inhibition at +10 dB)	multivariate	$F_{(7.71)}=11.01$, p=0.001	treatment·sex·genotype	saline	univariate	$F_{(1,16)}=0.06, p=0.810$	object
- split by sex		(,,,,) ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,		nicotine	univariate	$F_{(1,16)}=4.83$, p=0.043	object
males	multivariate	F _(3,36) =0.27, p=0.604	treatment·genotype	4h intertrial			
females	multivariate	F _(3,35) =14.41, p=0.001	treatment·genotype	(interaction time [s])	univariate	$F_{(15.64)} = 5.17$, p=0.026	treatment·object·
split by genotype					univariata	$E_{n-1} = 5.61 n = 0.021$	treatment:object:genotype
WT	multivariate	$F_{(1,18)}$ =6.03, p=0.024	treatment		univariate	$F_{(15,64)} = 0.13$ p=0.021	treatment
TG	multivariate	$F_{(1,17)}=9.17, p=0.008$	treatment		univariate	$F_{(1,04)}=0.13$, p=0.720 $F_{(1,04)}=0.53$, p=0.469	genotype
					univariate	(1,64)-0.55, p-0.409	genotype

	<u>analysis</u>	significance	factor		<u>analysis</u>	significance	factor
	univariate	F _(1.64) =0.01, p=0.996	object	Morris watermaze			
	univariate	$F_{(1,64)}$ =3.80, p=0.056	sex	escape training			
- split by genotype	• • .	E 117 0.040		(distance moved [m])	repeated measures	$F_{(4,146)}$ =0.69, p=0.617*	sex·treatment ·time·genotype
W1	univariate	$F_{(3,36)}=4.1/, p=0.049$	treatment-object		repeated	F _(4,146) =2.36, p=0.048*	treatment·time·genotype
split by treatment	univeriete	E = -2.67 = -0.120	object		repeated	$E_{4,40} = 5.72 \text{ p} < 0.001 \text{*}$	treatment
nicotine	univariate	$\Gamma_{(1,18)}=2.07, p=0.120$ E = 1.55 p=0.230	object		repeated	T (4,140)=5.72, p <0.001	deathent time
TC	univariate	$\Gamma_{(1,18)}$ -1.55, p=0.250 E = -4.28 p=0.046	traatmantichiaat		measures	F _(4,146) =1.67, p=0.153*	genotype·time
split by treatment	univariate	r _(3,36) -4.28, p-0.040	treatment object		measures	F _(4,146) =1.80, p=0.123*	sex·time
spin by treatment	univariata	E = -0.84 p - 0.371	object		repeated	F _(4,146) =66.22, p<0.001*	time
nicotine	univariate	$F_{(1,18)}=4.77, p=0.042$	object	- split by treatment	repeated	$E_{\rm resum} = 2.40 \text{ p} = 0.033$	genotype-time
Novelty preference				niastina	repeated	$\Gamma_{(6,108)} = 2.40, p = 0.033$	genotype time
(interaction time [s])	univariate	$E_{a,a} = 4.48 \text{ p} = 0.053$	sex.genotyne	mcoune	measures	$\Gamma_{(3,66)}=0.63, p=0.492^{+1}$	genotype unie
(interaction time [3])	univariate	$F_{(1,14)} = 4.40, p=0.0000$ $F_{(1,14)} = 1.19, p=0.203$	genotype	- split by genotype	repeated		
	univariate	$F_{(1,14)} = 0.03$ p=0.858	sex	WT	measures	F _(6,108) =5.22, p<0.001	treatment·time
	univariate	$1_{(1,14)} = 0.05, p=0.050$	SCA	TG	repeated measures	F _(3,67) =2.57, p=0.048*	treatment·time
(nose contact time [s])	univariate	$F_{(1,14)} = 5.76 \text{ p} = 0.031$	sex·genotype		manastad		sex-treatment
	univariate	$F_{(1,14)} = 0.13 \text{ p} = 0.720$	genotype	(velocity [cm/s])	measures	$F_{(4,145)}=0.34, p=0.874*$	·time·genotype
	univariate	$F_{(1,14)} = 0.08 p=0.781$	sex		repeated	F _(4,145) =3.93, p=0.003*	treatment·time
Operant conditioning					repeated	$E_{4,445}=1.50$ p=0.200*	genotype-time
(day 10 reward [N])	Kruskal	n<0.001	A groups		repeated	T (4,145)=1.50, p=0.200	genotype time
- post hoc	Wallis	p<0.001	4 groups		measures	$F_{(4,145)}=2.23, p=0.061*$	sex·time
WT saline vs WT nicotine	Dunnett-T3	p<0.001	2 groups		measures	$F_{(4,145)}=41.21, p<0.001*$	time
TG saline vs WT nicotine	Dunnett-T3	p < 0.001 p = 0.004	2 groups	- split by treatment	repeated measures repeated measures		
TG nicotine vs WT nicotine	Dunnett-T3	p=0.004	2 groups	saline		$F_{(6,108)}$ =1.02, p=0.418	genotype·time
TG nicotine vs WT saline	Dunnett-T3	p=0.322	2 groups 2 groups	nicotine		F _(3,68) =1.03, p=0.397	genotype time
TG nicotine vs TG saline	Dunnett-T3	p=0.761	2 groups	mamory tast			
	Kanalaal	P 0.001	2 Broups	(distance moved [m])	univariata	E0.75 p=0.389	treatment.guadrant.genotyne
(day 10 total nosepokes [N])	Wallis	p=0.001	4 groups	(uistance moved [m])	univariate	$F_{(7,72)}=0.73$, p=0.085	quadrant:genotype
- post hoc		0.001	2		univariate	$F_{(7,72)}=2.87$, p=0.035 $F_{(7,72)}=0.01$, p=0.929	treatment
W1 saline vs W1 nicotine	Dunnett-13	p=0.001	2 groups		univariate	$F_{(1,72)}=6.01, p=0.016$	genotype
TG saline vs w I nicotine	Dunnett-13	p=0.012	2 groups		univariate	$F_{(1,72)}=0.11$, p=0.010 $F_{(1,72)}=15.42$ n<0.001	quadrant
IG nicotine vs w I nicotine	Dunnett-13	p=0.156	2 groups	- split by genotype	univariate	r (1,/2)=13.42, p<0.001	quadrant
IG nicotine vs w I saline	Dunnett-13	p=0.550	2 groups	WT	univariate	$F_{(1,36)}=24.67, p<0.001$	quadrant
1G nicotine vs 1G saline	Dunnett-13	p=0.746	2 groups	split by treatment		(1,50)	.1
(day 1 total nosepokes [N])	Kruskal Wallis	p=0.190	4 groups	saline	univariate	F _(1,18) =0.48, p=0.002	quadrant
	vi anno			nicotine	univariate	F _(1,18) =0.92, p=0.003	quadrant

	<u>analysis</u>	significance	factor		<u>analysis</u>	significance	factor
TG				α 7 binding			
saline	univariate	F _(1,18) =1.32, p=0.048	quadrant	$\overline{([^{125}I] \alpha}$ -bungarotoxin	multivariate	F _(17,478) =0.64, p=0.861	treatment genotype region
nicotine	univariate	F _(1,18) =0.06, p=0.924	quadrant	[fmol·mg tissue equivalent-1])	multivariate	F _(1,478) =0.53, p=0.466	treatment genotype
- split by quadrant			-		multivariate	$F_{(17,478)}=1.18$, p=0.279	genotype region
error	univariate	F _(1,36) =0.39, p=0.538	genotype		multivariate	$F_{(17,478)}=0.46, p=0.970$	treatment region
target	univariate	F _(1,36) =7.14, p=0.011	genotype		multivariate	$F_{(17,478)}=112.08, p<0.001$	region
split by treatment					multivariate	$F_{(1,478)}$ =33.30, p<0.001	genotype
saline	univariate	F _(1,19) =1.98, p=0.177	genotype		multivariate	$F_{(1,478)}=0.47, p=0.492$	treatment
nicotine	univariate	F _(1,19) =5.66, p=0.029	genotype	- split by region		(1,) /1	
Autoradiography				cingulate cortex	multivariate	F _(1,28) =5.66, p=0.024	genotype
					multivariate	F _(1,28) =4.42, p=0.044	treatment genotype
$\alpha 4\beta 2*$ binding				post hoc			• • •
(cytisine-sens.[¹²³]epibatidine	multivariate	F _(27,719) =0.74, p=0.824	treatment·genotype·region	TG saline vs WT saline	Duncan's	p=0.006	2 groups
[Informing tissue equivalent-1])	multivariate	F _(1,719) =0.03, p=0.853	treatment·genotype	TG nicotine vs WT nicotine	Duncan's	p=0.847	2 groups
	multivariate	F _(27,719) =0.37, p=0.999	genotype region	basomedial amygdala	multivariate	$F_{(1,22)}=6.87, p=0.015$	genotype-treatment
	multivariate	$F_{(31,828)}=1.47, p=0.030$	treatment·region	post hoc			0 11
	multivariate	F _(27,719) =198.14, p<0.001	region	TG saline vs WT saline	Duncan's	p=0.025	2 groups
	multivariate	$F_{(1,719)}=75.51, p<0.001$	treatment	TG nicotine vs WT nicotine	e Duncan's	p=0.276	2 groups
	multivariate	F _(1,719) =1.40, p=0.237	genotype	ventral medial	multivoriata	E = -8.24 = -0.007	treatment construct
- split by region				hypothalamus	multivariate	$F_{(1,25)}=8.34, p=0.007$	treatment-genotype
caudate putamen	multivariate	$F_{(1,26)}=6.34, p=0.018$	treatment	post hoc			
preoptic area	multivariate	$F_{(1,25)}=4.50, p=0.043$	treatment	TG nicotine vs WT nicotine	e Duncan's	p=0.026	2 groups
lateral dorsal thalamic nuclei	multivariate	$F_{(1,26)}=6.14, p=0.020$	treatment	TG saline vs WT saline	Duncan's	p=0.141	2 groups
olfactory tubercles	multivariate	F _(1,25) =9.68, p=0.005	treatment	dentate gyrus	multivariate	$F_{(1,28)}$ =5.08, p=0.032	treatment·genotype
retrosplenial cortex	multivariate	F _(1,27) =12.42, p=0.002	treatment	post hoc			
hypothalamus	multivariate	F _(1,24) =16.00, p<0.001	treatment	TG nicotine vs WT nicotine	e Duncan's	p=0.049	2 groups
medial septum	multivariate	F _(1,23) =36.28, p<0.001	treatment	TG saline vs WT saline	Duncan's	p=0.268	2 groups
vertical diagonal band	multivariate	F _(1,22) =37.49, p<0.001	treatment	dorsal endopiriform	multivariate	F _(1,30) =5.73, p=0.023	genotype
hippocampus	multivariate	F _(1,27) =13.77, p<0.001	treatment	ventral medial geniculate	multivariate	F _(1,24) =4.46, p=0.045	genotype
frontal association	multivariate	F _(1,28) =39.31, p<0.001	treatment	CA1	multivariate	F _(1,25) =4.30, p=0.048	genotype
prelimbic cotrex	multivariate	F _(1,28) =59.27, p<0.001	treatment				
primary motor cortex	multivariate	F _(1,28) =66.40, p<0.001	treatment	* Greenhouse-Geisser corrected, as	s data are not s	pheric	
secondary motor cortex	multivariate	F _(1,28) =71.04, p<0.001	treatment				
cingulate cortex	multivariate	F _(1,28) =21.73, p<0.001	treatment				
somatosensory corex	multivariate	F _(1,28) =47.26, p<0.001	treatment				
piriform cortex	multivariate	F _(1,28) =29.58, p<0.001	treatment				
visual cortex	multivariate	F _(1,28) =25.00, p<0.001	treatment				
auditory cortex	multivariate	F _(1,21) =55.50, p<0.001	treatment				
interpedencular nucleus	multivariate	F _(1,27) =5.20, p=0.031	genotype				